Abstract 3324
Background
Active surveillance for CSI testicular cancer is currently based on serial radiological imaging and classic tumor markers (β-HCG, AFP, LDH). The management of borderline suspicious tumor markers negative enlarging nodes and of the post-chemotherapy residual disease is challenging, and currently relies on clinical follow-up with imaging to establish patterns of growth or pathological confirmation with biopsy or retroperitoneal lymphadenectomy (RPLND). A blood-based approach to reliably identify patients with non teratoma viable GCT (NTVGCT) would be valuable.
Methods
Plasma miR-371a-3p (miR371) of pts with GCT was analyzed by RT-PCR. Spike-in cel-miR-39-3p and miR-30b-5p as internal controls. miR-451a and miR-23a-3p were used as quality control for the hemolysis. The miR371 expression was used to calculate its area under the ROC curve, sensitivity and specificity in detecting viable NTGCT.
Results
One hundred samples from 79 patients (44 CSI and 35 metastatic) were analyzed. Nineteen CSI pts presented suspicious enlarging nodes (≥ IIA) during surveillance and 8/19 had confirmed relapse. miR371 predicted the clinical relapse in 6/8 of pts while the 11 CSI pts with unconfirmed enlarging nodes were all negative for miR-371. miR371 was expressed in all the pre-chemotherapy metastatic pts and negative after chemotherapy (n = 25). miR371 was negative in all the pts with post-chemotherapy residual radiographic findings (n = 24). No residual NTVGCT was detected in any of these 24 pts by either pathology at resection (n = 16) or clinical follow-up (n = 8). The area under the ROC curve was 0.94, the sensitivity and specificity were 89% and 98%, respectively. The results showed a high concordance comparing 2 independent experiments conducted in house and in an outside lab (r = 0.98 and 0.87, respectively).
Conclusions
Detectable circulating miR371 expression predicts the presence of NTVGCT. If validated in larger real world settings, this may result in significant change in the practice for all patients with germ cell tumors by moving it to a biological rather than radiological decision base. These encouraging findings inform upcoming North American trials for further definition of miR371 operating characteristics in GCTs.
Clinical trial identification
Legal entity responsible for the study
Lucia Nappi.
Funding
GUMOC research grant 2017.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract